Q-omics provides the consensus-scored TMEM251 profile across patient tissues and cancer cell-line models. TMEM251 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM251 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TMEM251 RNA expression shows 18,567 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where TMEM251 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM251 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM251 survival associations across molecular data types. TMEM251 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM251 RNA expression–survival associations across cancer types. High TMEM251 expression shows unfavorable associations in UVM, LIHC and ACC, but favorable associations in OV, KIRC and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM251 RNA expression.
This table summarizes TMEM251 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM251. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM251 shows lower tumor expression in KICH, THCA and COAD and higher tumor expression in HNSC, LIHC and BLCA. The HNSC box plot shows higher TMEM251 RNA expression in tumor versus normal tissue (log2 FC = +1.044, t-test p < 0.001).
This table shows molecular features associated with TMEM251 in patient tissues and cancer cell lines. In patient samples, TMEM251 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM251 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
